Straits Times Index
3,173.13 -14.53 (-0.46%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,195.33 -190.54 (-1.16%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
63,219.99 +2,290.76 (+3.76%) CMC Crypto 200
1,279.78 -32.84 (-2.50%)
electroCore, Inc. (ECOR)
| Previous close | 5.62 |
| Open | 5.92 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.63 - 5.92 |
| 52-week range | 3.83 - 8.08 |
| Volume | |
| Avg. volume | 11,709 |
| Market cap | 33.855M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
electroCore Announces the Launch of Truvaga Plus® for General Wellness
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand. Truvaga Plus is engineer
- GlobeNewswire
electroCore Expands Intellectual Property Portfolio
electroCore Granted Two New U.S. PatentsROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology: US Patent No. 11,944,815 entitled “Non-Invasive Nerve Sti
- GlobeNewswire
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Reported record full year of 2023 revenu
